5 February 2021: OIA response | Cost of funding emtricitabine with tenofovir disoproxil

5 February 2021 

Dear [name and contact details withheld]

REQUEST FOR INFORMATION

Thank you for your request dated 6 January 2021 under the Official Information Act 1982 (OIA) for information relating to emtricitabine with tenofovir disoproxil.  You asked for:

A monetary value of the cost spent funding Truvada, otherwise known as PrEP, for the period from 1 January 2018 up to and including 31 December 2020, or as close to this date as possible, including partial funding.

Please find the information you have requested provided in the table below. 

Brand name

2018

2019

2020

Truvada

$9,948,856.98

$1,889,091.70

$0.00

Teva

$0.00

$1,412,600.40

$2,194,349.41

Note: figures provided are the gross cost (excluding any applicable rebates) of funding spent per calendar year

Note:

  1. Emtricitabine with tenofovir disoproxil is used for multiple indications including, but not limited to, pre-exposure prophylaxis (PrEP), confirmed HIV and prevention of maternal transmission.
  2. The Teva brand of emtricitabine with tenofovir disoproxil has been listed in the Pharmaceutical Schedule since April 2019.
  3. The Truvada brand of emtricitabine with tenofovir disoproxil was delisted from the Pharmaceutical Schedule in September 2019.

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.

Yours sincerely

Rachel Read
Manager, Policy and Government Services